Tilray® Expands Global Presence with Successful Export to Switzerland
17 December 2019 - 7:00PM
Business Wire
Switzerland becomes the 14th country where
patients can access Tilray medical cannabis products
Tilray, Inc. (“Tilray” or “the Company”) (NASDAQ: TLRY), a
global leader in medical cannabis research, cultivation, production
and distribution, today announced it has successfully exported
medical cannabis extracts to Switzerland. Tilray’s entry into
Switzerland marks the fourteenth country to distribute Tilray’s
medical cannabis products, from its Good Manufacturing Practices
(GMP)-certified production facility, to patients in need.
“We’re proud to deliver Tilray’s medical cannabis to Swiss
patients in need as we continue our expansion into Europe and
around the globe,” says Sascha Mielcarek, Tilray’s Managing
Director in Europe. “Tilray is committed to quality and patient
safety and we look forward to significantly improving the quality
of lives of Swiss patients through our medical cannabis
products.”
The import and export permits were received in early December
2019, with the shipment of Tilray’s medical cannabis extracts
successfully arriving in Switzerland on December 13. Following this
first shipment of extracts, Tilray also anticipates exporting dried
medical cannabis to Switzerland, offering patients an assortment of
form factors to meet their varying medical indications.
Last week, Tilray announced it received an additional GMP
certification for its EU campus in Portugal, allowing the site to
supply medical cannabis products to international patients,
partners and markets. Tilray expects to supply its European
partners from its EU campus in Cantanhede, Portugal beginning
2020.
About Tilray® Tilray is a global pioneer in the research,
cultivation, production and distribution of cannabis and
cannabinoids currently serving tens of thousands of patients and
consumers in 14 countries spanning five continents.
Cautionary note regarding forward-looking statements:
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements or
forward-looking-information in this press release may be identified
by the use of words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions. Forward-looking statements are not a guarantee of
future performance, future action or any particular result to
clinical trials, and are based upon a number of estimates and
assumptions of management in light of management’s experience and
perception of trends, current conditions and expected developments,
as well as other factors that management believes to be relevant
and reasonable in the circumstances, including assumptions in
respect of current and future market conditions, the current and
future medical and adult-use cannabis regulatory environment,
medical cannabis demand and market structure and future approvals
and permits. Actual results, performance or achievement could
differ materially from that expressed in, or implied by, any
forward-looking statements in this press release, and, accordingly,
you should not place undue reliance on any such forward-looking
statements and they are not guarantees of future results. Please
see the heading “Risk Factors” in Tilray’s Quarterly Report on Form
10-Q, which was filed with the U.S. Securities and Exchange
Commission and Canadian securities regulators on November 13, 2019,
assumptions, uncertainties and other factors that may cause actual
future results or anticipated events to differ materially from
those expressed or implied in any forward-looking statements.
Tilray does not undertake and specifically declines any obligation
to update any forward-looking statements that are included herein,
except in accordance with applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191217005028/en/
Media: Chrissy Roebuck, +1-833-206-8161,
news@tilray.com Investors: Rachel
Perkins, +1-646-277-1221, rachel.perkins@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Apr 2024 to May 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From May 2023 to May 2024